FULC vs. BHVN, EVO, ETNB, JANX, ANIP, EWTX, MESO, TVTX, CVAC, and CALT
Should you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Biohaven (BHVN), Evotec (EVO), 89BIO (ETNB), Janux Therapeutics (JANX), ANI Pharmaceuticals (ANIP), Edgewise Therapeutics (EWTX), Mesoblast (MESO), Travere Therapeutics (TVTX), CureVac (CVAC), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry.
Fulcrum Therapeutics vs. Its Competitors
Fulcrum Therapeutics (NASDAQ:FULC) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.
In the previous week, Biohaven had 11 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 14 mentions for Biohaven and 3 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.78 beat Biohaven's score of 0.31 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.
Fulcrum Therapeutics has a beta of 2.37, indicating that its share price is 137% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
Fulcrum Therapeutics has higher revenue and earnings than Biohaven. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Fulcrum Therapeutics' return on equity of -0.20% beat Biohaven's return on equity.
Fulcrum Therapeutics currently has a consensus price target of $6.29, suggesting a potential downside of 19.83%. Biohaven has a consensus price target of $58.46, suggesting a potential upside of 340.45%. Given Biohaven's stronger consensus rating and higher possible upside, analysts clearly believe Biohaven is more favorable than Fulcrum Therapeutics.
89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 7.0% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 14.6% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Fulcrum Therapeutics beats Biohaven on 8 of the 15 factors compared between the two stocks.
Get Fulcrum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulcrum Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FULC) was last updated on 7/16/2025 by MarketBeat.com Staff
Free FULC Stock Alerts